Identification and validation of HOXB3 hypomethylation as a novel prognostically epigenetic biomarker in acute myeloid leukemia
<i>HOXB3</i> hypomethylation, which is associated with <i>HOXB3</i> overexpression, is a frequent event in AML. AML with <i>HOXB3</i> hypomethylation usually has unique genetic patterns such as a normal karyotype, cytogenetic/molecular-intermediate risk, and mutations in <i>FLT3</i>-ITD, <i>NPM1</i> and <i>DNMT3A</i>. Despite these associations, <i>HOXB3</i> hypomethylation may serve as an independent prognostic biomarker for AML.
Authors
- Ting‐juan Zhang (ORCID: https://orcid.org/0000-0003-1533-0646)
- Zi‐jun Xu (ORCID: https://orcid.org/0000-0002-5051-6799)
- Ming‐qiang Chu
- Xudong Wu (ORCID: https://orcid.org/0000-0002-9231-2401)
- Fei Xie (ORCID: https://orcid.org/0000-0002-3636-2682)
- Ran Chang
- Jing-dong Zhou
- Jun Qian
Institutions
- Jiangsu University (CN)
- Affiliated Hospital of Jiangsu University (CN)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2026-01-12
- DOI
- https://doi.org/10.3389/fimmu.2025.1709417
- Primary Topic
- Acute Myeloid Leukemia Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00